Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Interest & Investment Income (2018 - 2025)

Marimed has reported Interest & Investment Income over the past 8 years, most recently at $103000.0 for Q4 2025.

  • Quarterly Interest & Investment Income rose 171.05% to $103000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $177000.0 through Dec 2025, up 55.26% year-over-year, with the annual reading at $177000.0 for FY2025, 55.26% up from the prior year.
  • Interest & Investment Income was $103000.0 for Q4 2025 at Marimed, up from $25000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $318000.0 in Q2 2022 and troughed at $13000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $31500.0 (2021), against an average of $81450.0.
  • Year-over-year, Interest & Investment Income skyrocketed 1738.46% in 2022 and then plummeted 88.7% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $13000.0 in 2021, then skyrocketed by 1738.46% to $239000.0 in 2022, then plummeted by 88.7% to $27000.0 in 2023, then soared by 40.74% to $38000.0 in 2024, then skyrocketed by 171.05% to $103000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Interest & Investment Income are $103000.0 (Q4 2025), $25000.0 (Q3 2025), and $25000.0 (Q2 2025).